Morgan Stanley Maintains Equal-Weight on 10x Genomics, Raises Price Target to $40
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Tejas Savant maintains 10x Genomics (NASDAQ:TXG) with a Equal-Weight and raises the price target from $37 to $40.
Morgan Stanley analyst Tejas Savant maintains 10x Genomics (NASDAQ:TXG) with a Equal-Weight and raises the price target from $37 to $40.